{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:00:11Z","timestamp":1793228411259,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1038\/leu.2017.152","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T06:41:49Z","timestamp":1495435309000},"page":"2686-2694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth"],"prefix":"10.1038","volume":"31","author":[{"given":"J","family":"Delgado-Calle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M D","family":"Cregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K W","family":"Condon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Kuhstoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L I","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G D","family":"Roodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"BFleu2017152_CR1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","volume":"109","author":"GD Roodman","year":"2010","unstructured":"Roodman GD . Pathogenesis of myeloma bone disease. J Cell Biochem 2010; 109: 283\u2013291.","journal-title":"J Cell Biochem"},{"key":"BFleu2017152_CR2","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC . Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015; 125: 3049\u20133058.","journal-title":"Blood"},{"key":"BFleu2017152_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/SPC.0b013e328349c524","volume":"5","author":"R Silbermann","year":"2011","unstructured":"Silbermann R, Roodman GD . Bone effects of cancer therapies: pros and cons. Curr Opin Support Palliat Care 2011; 5: 251\u2013257.","journal-title":"Curr Opin Support Palliat Care"},{"key":"BFleu2017152_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s00774-009-0154-7","volume":"28","author":"GD Roodman","year":"2010","unstructured":"Roodman GD . Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010; 28: 244\u2013250.","journal-title":"J Bone Miner Metab"},{"key":"BFleu2017152_CR5","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1359\/jbmr.2002.17.11.1921","volume":"17","author":"GD Roodman","year":"2002","unstructured":"Roodman GD . Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002; 17: 1921\u20131925.","journal-title":"J Bone Miner Res"},{"key":"BFleu2017152_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","volume":"76","author":"J Delgado-Calle","year":"2016","unstructured":"Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N et al. Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res 2016; 76: 1089\u20131100.","journal-title":"Cancer Res"},{"key":"BFleu2017152_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","volume":"8","author":"J Delgado-Calle","year":"2014","unstructured":"Delgado-Calle J, Bellido T, Roodman GD . Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care 2014; 8: 407\u2013413.","journal-title":"Curr Opin Support Palliat Care"},{"key":"BFleu2017152_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jbmr.2741","volume":"31","author":"D Toscani","year":"2016","unstructured":"Toscani D, Palumbo C, Dalla PB, Ferretti M, Bolzoni M, Marchica V et al. The proteasome inhibitor bortezomib maintains osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: a new function for proteasome inhibitors. J Bone Miner Res 2016; 31: 815\u2013827.","journal-title":"J Bone Miner Res"},{"key":"BFleu2017152_CR9","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/leu.2011.381","volume":"26","author":"N Giuliani","year":"2012","unstructured":"Giuliani N, Ferretti M, Bolzoni M, Storti P, Lazzaretti M, Dalla PB et al. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 2012; 26: 1391\u20131401.","journal-title":"Leukemia"},{"key":"BFleu2017152_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/er.2012-1026","volume":"34","author":"SL Dallas","year":"2013","unstructured":"Dallas SL, Prideaux M, Bonewald LF . The osteocyte: an endocrine cell... and more. Endocr Rev 2013; 34: 658\u2013690.","journal-title":"Endocr Rev"},{"key":"BFleu2017152_CR11","doi-asserted-by":"publisher","first-page":"E478","DOI":"10.1073\/pnas.1409857112","volume":"112","author":"X Tu","year":"2015","unstructured":"Tu X, Delgado-Calle J, Condon KW, Maycas M, Zhang H, Carlesso N et al. Osteocytes mediate the anabolic actions of canonical Wnt\/\u03b2-catenin signaling in bone. Proc Natl Acad Sci USA 2015; 112: E478\u2013E486.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017152_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00223-013-9774-y","volume":"94","author":"T Bellido","year":"2013","unstructured":"Bellido T . Osteocyte-driven bone remodeling. Calcif Tissue Int 2013; 94: 25\u201334.","journal-title":"Calcif Tissue Int"},{"key":"BFleu2017152_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40610-015-0026-y","volume":"1","author":"J Delgado-Calle","year":"2015","unstructured":"Delgado-Calle J, Bellido T . Osteocytes and skeletal pathophysiology. Curr Mol Biol Rep 2015; 1: 157\u2013167.","journal-title":"Curr Mol Biol Rep"},{"key":"BFleu2017152_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrendo.2016.71","volume":"12","author":"LI Plotkin","year":"2016","unstructured":"Plotkin LI, Bellido T . Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat Rev Endocrinol 2016; 12: 593\u2013605.","journal-title":"Nat Rev Endocrinol"},{"key":"BFleu2017152_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron R, Kneissel M . WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013; 19: 179\u2013192.","journal-title":"Nat Med"},{"key":"BFleu2017152_CR16","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","volume":"19","author":"KE Poole","year":"2005","unstructured":"Poole KE, Van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19: 1842\u20131844.","journal-title":"FASEB J"},{"key":"BFleu2017152_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T . Role and mechanism of action of sclerostin in bone. Bone 2017; 96: 29\u201337.","journal-title":"Bone"},{"key":"BFleu2017152_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","volume":"96","author":"MS Ominsky","year":"2017","unstructured":"Ominsky MS, Boyce RW, Li X, Ke HZ . Effects of sclerostin antibodies in animal models of osteoporosis. Bone 2017; 96: 63\u201375.","journal-title":"Bone"},{"key":"BFleu2017152_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/er.2011-1060","volume":"33","author":"HZ Ke","year":"2012","unstructured":"Ke HZ, Richards WG, Li X, Ominsky MS . Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012; 33: 747\u2013783.","journal-title":"Endocr Rev"},{"key":"BFleu2017152_CR20","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.27342","volume":"131","author":"E Terpos","year":"2012","unstructured":"Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 2012; 131: 1466\u20131471.","journal-title":"Int J Cancer"},{"key":"BFleu2017152_CR21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/jbmr.2789","volume":"31","author":"H Eda","year":"2016","unstructured":"Eda H, Santo L, Wein MN, Hu DZ, Cirstea DD, Nemani N et al. Regulation of sclerostin expression in multiple myeloma by Dkk-1; a potential therapeutic strategy for myeloma bone disease. J Bone Miner Res 2016; 31: 1225\u20131234.","journal-title":"J Bone Miner Res"},{"key":"BFleu2017152_CR22","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23: 860\u2013869.","journal-title":"J Bone Miner Res"},{"key":"BFleu2017152_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/sj.thj.6200052","volume":"1","author":"K Asosingh","year":"2000","unstructured":"Asosingh K, Radl J, Van R, I Van CB, Vanderkerken K . The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000; 1: 351\u2013356.","journal-title":"Hematol J"},{"key":"BFleu2017152_CR24","first-page":"593","volume":"132","author":"J Radl","year":"1988","unstructured":"Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM . Animal model of human disease. Multiple myeloma. Am J Pathol 1988; 132: 593\u2013597.","journal-title":"Am J Pathol"},{"key":"BFleu2017152_CR25","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","volume":"118","author":"S D'Souza","year":"2011","unstructured":"D'Souza S, del PD, Jin S, Sun Q, Huston AJ, Kostov FE et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood 2011; 118: 6871\u20136880.","journal-title":"Blood"},{"key":"BFleu2017152_CR26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/jbmr.3011","volume":"32","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Tu X, Pacheco-Costa R, McAndrews K, Edwards R, Pellegrini G et al. Control of bone anabolism in response to mechanical loading and PTH by distinct mechanisms downstream of the PTH receptor. J Bone Miner Res 2017; 32: 522\u2013535.","journal-title":"J Bone Miner Res"},{"key":"BFleu2017152_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013; 28: 2\u201317.","journal-title":"J Bone Miner Res"},{"key":"BFleu2017152_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1517\/14712598.2015.978853","volume":"15","author":"YM Papamerkouriou","year":"2015","unstructured":"Papamerkouriou YM, Kenanidis E, Gamie Z, Papavasiliou K, Kostakos T, Potoupnis M et al. Treatment of multiple myeloma bone disease: experimental and clinical data. Expert Opin Biol Ther 2015; 15: 213\u2013230.","journal-title":"Expert Opin Biol Ther"},{"key":"BFleu2017152_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","volume":"2","author":"R Silbermann","year":"2013","unstructured":"Silbermann R, Roodman GD . Myeloma bone disease: Pathophysiology and management. J Bone Oncol 2013; 2: 59\u201369.","journal-title":"J Bone Oncol"},{"key":"BFleu2017152_CR30","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","volume":"106","author":"N Giuliani","year":"2005","unstructured":"Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S et al. Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472\u20132483.","journal-title":"Blood"},{"key":"BFleu2017152_CR31","doi-asserted-by":"publisher","first-page":"33132","DOI":"10.1074\/jbc.M500608200","volume":"280","author":"T Gaur","year":"2005","unstructured":"Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 2005; 280: 33132\u201333140.","journal-title":"J Biol Chem"},{"key":"BFleu2017152_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/cr.2008.13","volume":"18","author":"PV Bodine","year":"2008","unstructured":"Bodine PV . Wnt signaling control of bone cell apoptosis. Cell Res 2008; 18: 248\u2013253.","journal-title":"Cell Res"},{"key":"BFleu2017152_CR33","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1210\/en.2013-1905","volume":"155","author":"X Li","year":"2014","unstructured":"Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M et al. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology 2014; 155: 4785\u20134797.","journal-title":"Endocrinology"},{"key":"BFleu2017152_CR34","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1210\/en.2011-0252","volume":"152","author":"X Li","year":"2011","unstructured":"Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology 2011; 152: 3312\u20133322.","journal-title":"Endocrinology"},{"key":"BFleu2017152_CR35","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/jbmr.3038","volume":"32","author":"SW Kim","year":"2016","unstructured":"Kim SW, Lu Y, Williams EA, Lai F, Lee JY, Enishi T et al. Sclerostin antibody administration converts bone lining cells into active osteoblasts. J Bone Miner Res 2016; 32: 892\u2013901.","journal-title":"J Bone Miner Res"},{"key":"BFleu2017152_CR36","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jbmr.2869","volume":"31","author":"AY Sato","year":"2016","unstructured":"Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M et al. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost\/sclerostin. J Bone Miner Res 2016; 31: 1791\u20131802.","journal-title":"J Bone Miner Res"},{"key":"BFleu2017152_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.239","volume":"54","author":"D Padhi","year":"2014","unstructured":"Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 2014; 54: 168\u2013178.","journal-title":"J Clin Pharmacol"},{"key":"BFleu2017152_CR38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, ez-Perez A et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412\u2013420.","journal-title":"N Engl J Med"},{"key":"BFleu2017152_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass","year":"2005","unstructured":"Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8: 751\u2013764.","journal-title":"Dev Cell"},{"key":"BFleu2017152_CR40","doi-asserted-by":"publisher","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ . Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 2011; 6: e25900.","journal-title":"PLoS ONE"},{"key":"BFleu2017152_CR41","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1128\/MCB.05980-11","volume":"31","author":"W Wei","year":"2011","unstructured":"Wei W, Zeve D, Suh JM, Wang X, Du Y, Zerwekh JE et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol Cell Biol 2011; 31: 4706\u20134719.","journal-title":"Mol Cell Biol"},{"key":"BFleu2017152_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/10428190903503438","volume":"51","author":"S Yaccoby","year":"2010","unstructured":"Yaccoby S . Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 2010; 51: 213\u2013220.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017152_CR43","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. . Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106\u20132111.","journal-title":"Blood"},{"key":"BFleu2017152_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1359\/jbmr.081104","volume":"24","author":"DJ Heath","year":"2009","unstructured":"Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr., Evans HR et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009; 24: 425\u2013436.","journal-title":"J Bone Miner Res"},{"key":"BFleu2017152_CR45","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","volume":"113","author":"YW Qiang","year":"2009","unstructured":"Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling. Blood 2009; 113: 4319\u20134330.","journal-title":"Blood"},{"key":"BFleu2017152_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1586\/17474086.2013.874943","volume":"7","author":"E Terpos","year":"2014","unstructured":"Terpos E, Berenson J, Raje N, Roodman GD . Management of bone disease in multiple myeloma. Expert Rev Hematol 2014; 7: 113\u2013125.","journal-title":"Expert Rev Hematol"},{"key":"BFleu2017152_CR47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/SPC.0b013e3283565c56","volume":"6","author":"S Eshaghian","year":"2012","unstructured":"Eshaghian S, Berenson JR . Multiple myeloma: improved outcomes with new therapeutic approaches. Curr Opin Support Palliat Care 2012; 6: 330\u2013336.","journal-title":"Curr Opin Support Palliat Care"},{"key":"BFleu2017152_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS . Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011; 365: 62\u201370.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2017152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017152","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:30:48Z","timestamp":1719214248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["BFleu2017152"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.152","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]},"assertion":[{"value":"15 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GDR has received consulting honoraria from Amgen Inc. SAK is an employee of Lilly Research Laboratories. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}